Bayer at BPI West 2027
Mar 16–18, 2027 San Diego, CA ~800 attendees Website
Bayer takes part in 5 sessions at BPI West 2027 in San Diego. Its sessions centre on cell therapy development and cost-saving changes to licensed processes. They cover the process and analytical platforms behind a Phase III allogeneic cell therapy for Parkinson's disease and a CMC case study on bringing a lower-cost resin into a licensed process.
| Organization | BPI West 2027 Attendance |
|---|---|
Bayer Leverkusen, Germany | |
Global pharmaceutical company with cell and gene therapy programs alongside its marketed medicines. | Talk Wed Mar 17 9:30am–10:00am Talk Wed Mar 17 10:00am–10:30am Product Development of a Phase III (and Beyond) Parkinson’s Allogeneic Cell Therapy using Process and Analytic Platforms How automated 2D and 3D culture platforms aim to make dopamine neurons for Parkinson's as an off-the-shelf therapy, cheaper and at scale. Talk Thu Mar 18 9:00am–9:30am Talk Thu Mar 18 9:00am–9:30am Implementing a Lower-Cost Resin in a Licensed Process: A CMC Case Study How an approved drug's purification switched to a cheaper chromatography resin, with small-scale tests showing the product unchanged through commercial validation. Talk Thu Mar 18 4:15pm–4:45pm |
Instantly find 20 buyers from Bayer
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by BioProcess International or its organizers. Submit a correction